Abstract
Translational research encompasses the effective movement of new knowledge and discoveries into new approaches for prevention, diagnosis, and treatment of disease. There are many roadblocks to successful bench to bedside research, but few have received as much recent attention as the "valley of death." The valley of death refers to the lack of funding and support for research that moves basic science discoveries into diagnostics, devices, and treatments in humans, and is ascribed to be the result of companies unwilling to fund research development that may not result in a drug or device that will be utilized in the clinic and conversely, the fact that researchers have no access to the funding needed to carry out preclinical and early clinical development to demonstrate potential efficacy in humans. The valley of death also exists because bridging the translational gap is dependent on successfully managing an additional four risks: scientific, intellectual property, market, and regulatory. The University of Michigan (UM) has partnered with the Wallace H. Coulter Foundation (CF) to create a model providing an infrastructure to overcome these risks. This model is easily adoptable to other academic medical centers (AMCs). Clin Trans Sci 2010; Volume 3: 316-318.
Original language | English (US) |
---|---|
Pages (from-to) | 316-318 |
Number of pages | 3 |
Journal | Clinical and translational science |
Volume | 3 |
Issue number | 6 |
DOIs | |
State | Published - Dec 2010 |
Externally published | Yes |
Keywords
- Medical school administration
- Pilot programs
- Translational continuum
- University-foundation partnerships
- Valley of death
ASJC Scopus subject areas
- General Neuroscience
- General Biochemistry, Genetics and Molecular Biology
- Pharmacology, Toxicology and Pharmaceutics(all)